Newsroom
Category
June 2, 2026
Written by: Jane Alvarez Hernandez and Steve Lee The University of Texas at San Antonio (UT San Antonio) and its academic health center, UT Health San Antonio, recently received over $2.7 million in new academic and prevention awards from the Cancer Prevention and Research Institute of Texas (CPRIT), announced on Wednesday, May 20, to further […]
May 20, 2026
UT Health San Antonio is using AI-assisted colonoscopy technology to help physicians detect precancerous polyps in real time, expanding access to advanced colorectal cancer prevention and early detection for South Texans.
May 19, 2026
Like a busy restaurant kitchen, our cells depend on well-organized working spaces to assemble the “recipes” that keep the body healthy. UT San Antonio scientist, David Libich, PhD, recently received a five-year, $2.1 million Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences to study how certain proteins form these organizational hubs and what happens when things do not go according to plan.
May 19, 2026
Scientists at The University of Texas at San Antonio (UT San Antonio) are investigating a major immune system pathway that leads to the development of chronic pain and a drug that has the potential to stop the process in its tracks. Their study, published April 22 in Cell Reports, is the first of its kind to show a path toward the prevention of chronic pain.
May 5, 2026
From the moment of diagnosis, UT Health San Antonio patients are connected to a system designed to expand their treatment possibilities and bring the full strength of medicine and research to their care. Specialized programs focus on common and rare cancers, which allows for more personalized treatment approaches. For those at increased risk, services such as cancer genetics counseling and risk-reduction clinics offer early insight and prevention strategies.
April 23, 2026
Written by: Claire Kowalick More than 70% of cancers — including breast, bladder, cervical and lung cancer — show evidence of mutations linked to a group of enzymes called apolipoprotein B mRNA-editing enzyme catalytic polypeptides, or APOBEC. “APOBEC mutagenesis is the second-largest source of mutation in cancer and, importantly, the largest one we can do […]
